A61K 31 - Medicinal preparations containing organic active ingredients

Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
10/2011
10/25/2011	CA2379974C Preparation of compounds useful for the detection of hypoxia
10/25/2011	CA2341601C Use of selenium for treating patients suffering from systemic inflammatory response syndrome (sirs), and composition for implementing said treatment
10/25/2011	CA2330131C Method for the treatment of fertility disorders
10/25/2011	CA2302228C Sterilized 5-aminolevulinic acid
10/21/2011	WO2010121245A1 Method of treating hepatocellular carcinoma
10/21/2011	CA2796624A1 Method of treating hepatocellular carcinoma
10/20/2011	WO2011130741A1 Compounds for treating neurodegenerative diseases
10/20/2011	WO2011130740A2 Pyridylthiazole-based ureas as inhibitors of rho associated protein kinase (rock) and methods of use
10/20/2011	WO2011130728A1 Synthetic metabolites of fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention diseases and conditions
10/20/2011	WO2011130707A2 Compounds, compositions, and methods for reducing or eliminating bitter taste
10/20/2011	WO2011130697A2 Tissue targeting
10/20/2011	WO2011130692A2 Androgen induced oxidative stress inhibitors
10/20/2011	WO2011130677A1 Inhibitors of cancer stem cells
10/20/2011	WO2011130646A1 Anti-bacterial applications of poly -n-acetylglucosamine nanofibers
10/20/2011	WO2011130628A1 Treatment of cancers having k-ras mutations
10/20/2011	WO2011130616A1 Pyrrolobenzodiazepines used to treat proliferative diseases
10/20/2011	WO2011130615A2 Preparation of lacosamide
10/20/2011	WO2011130605A2 Compositions and methods for treating pulmonary hypertension
10/20/2011	WO2011130599A1 Polymeric conjugates of adenine nucleoside analogs
10/20/2011	WO2011130575A1 Modular glycan arrays
10/20/2011	WO2011130573A1 Fuel and chemical production from oleaginous yeast
10/20/2011	WO2011130566A2 Method for treating solid tumors
10/20/2011	WO2011130557A2 Phosphonates with reduced toxicity for treatment of viral infections
10/20/2011	WO2011130515A1 Arylthiazolyl piperidines and related compounds as modulators of survival motor neuron (smn) protein production
10/20/2011	WO2011130498A1 Micrornas that chemosensitize the apoptotic effect of 17-aag
10/20/2011	WO2011130486A2 Combination treatments and formulations for cancer
10/20/2011	WO2011130481A1 Pyrrolopyrazinone inhibitors of kinases
10/20/2011	WO2011130478A1 Phthalazin-(2h)-one inhibitors of kinases
10/20/2011	WO2011130476A2 Polymer-based therapeutic agents
10/20/2011	WO2011130462A2 Intraocular pressure reduction with intracameral bimatoprost implants
10/20/2011	WO2011130455A1 Dermal pharmaceutical compositions of 1-methyl-2',6'-pipecoloxylidide and method of use
10/20/2011	WO2011130429A2 Methods and materials for treating lung cancer
10/20/2011	WO2011130419A2 Broad spectrum antiviral and antiparasitic agents
10/20/2011	WO2011130411A1 Compositions and methods for treating visual disorders
10/20/2011	WO2011130400A1 Methods for providing enhanced resveratrol activity using 4-acetoxy-resveratrol
10/20/2011	WO2011130395A1 Inhibitors of flip to treat cancer
10/20/2011	WO2011130390A1 2, 4-pyrimidinediamine compounds and prodrugs thereof and their uses
10/20/2011	WO2011130383A1 Compounds containing fused rings which inhibit beta-secretase activity and methods of use thereof
10/20/2011	WO2011130379A1 Benzonapthyridine compositions and uses thereof
10/20/2011	WO2011130359A1 Compositions and methods for preventing joint destruction in osteoarthritis
10/20/2011	WO2011130356A2 Systems and methods for activating cross-linking in an eye
10/20/2011	WO2011130342A1 FUSED DERIVATIVES AS ΡI3Κδ INHIBITORS
10/20/2011	WO2011130317A2 Therapeutic agents having reduced toxicity
10/20/2011	WO2011130302A2 Method of treating obesity using antioxidant inflammation modulators
10/20/2011	WO2011130271A1 Novel organo-palladium complexes
10/20/2011	WO2011130232A1 Combination comprising a cyclin dependent kinase 4 or cyclin dependent kinase (cdk4/6) inhibitor and an mtor inhibitor for treating cancer
10/20/2011	WO2011130206A1 Polymer composition with phytochemical and dialysis membrane formed from the polymer composition
10/20/2011	WO2011130194A2 Methods for producing viloxazine salts and novel polymorphs thereof
10/20/2011	WO2011130163A1 Substituted hydroxamic acids and uses thereof
10/20/2011	WO2011130146A1 5, 7-substituted-imidazo [1, 2-c] pyrimidines as inhibitors of jak kinases
10/20/2011	WO2011130086A1 Pyridone derivatives
10/20/2011	WO2011130065A1 RNA INTERFERENCE MEDIATED INHIBITION OF MET GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
10/20/2011	WO2011129936A2 Compositions and methods for the prevention and treatment of cancer
10/20/2011	WO2011129837A1 Use of a 4-hydroxytoremifene prodrug for treatment of breast cancer
10/20/2011	WO2011129812A1 Oral testosterone ester formulations and methods of treating testoterone deficiency comprising same
10/20/2011	WO2011129796A1 5,11,17,23-tetrakis[bis(dihydroxyphosphoryl)methyl]calix[4]arene or the na salt thereof as fibrin polymerization inhibitors
10/20/2011	WO2011129792A1 Water dispersible formulations comprising cefpodoxime proxetil
10/20/2011	WO2011129765A1 Synergistic interaction of at least one vitamin e component and tyrosinase inhibitors for dermatological applications
10/20/2011	WO2011129716A1 Means for the prophylaxis and treatment of acute and chronic pancreatitis
10/20/2011	WO2011129627A2 Docetaxel-loaded thermosensitive liquid suppository composition for rectal administration
10/20/2011	WO2011129579A2 Oral pharmaceutical composition comprising fenofibric acid and an alkalifying agent
10/20/2011	WO2011129549A2 Anticancer drug delivery system using ph-sensitive metal nanoparticles
10/20/2011	WO2011129516A1 Decursinol derivative, a production method for the same and a pharmaceutical composition comprising the same
10/20/2011	WO2011129497A1 Adhesive hydrous gel sheet
10/20/2011	WO2011129494A1 Nucleolin specific aptamer and use thereof
10/20/2011	WO2011129461A1 Method and ophthalmic composition for treating retinal disease
10/20/2011	WO2011129457A1 Pharmaceutical composition for treating macular edema
10/20/2011	WO2011129427A1 Diagnostic agent and therapeutic agent for cancer
10/20/2011	WO2011129424A1 Pharmaceutical agent for prevention and/or treatment of htlv-1-associated myelopathy
10/20/2011	WO2011129399A1 Srebp inhibitor
10/20/2011	WO2011129379A1 Novel anti-hsp90 monoclonal antibody
10/20/2011	WO2011129371A1 GENE GROUP CAPABLE OF ENHANCING ANTI-TUMOR EFFECT OF 5-FU ALONE OR IFN-α/5-FU COMBINATION
10/20/2011	WO2011129365A1 Antitumor agent
10/20/2011	WO2011129095A1 Pyridone derivative having integrase inhibitory activity
10/20/2011	WO2011128914A2 Extended release pharmaceutical compositions of pramipexole
10/20/2011	WO2011128910A2 A drug delivery solid dosage formulation of sirolimus
10/20/2011	WO2011128906A1 Ciprofloxacin dry syrup composition
10/20/2011	WO2011128869A1 Amorphous roxithromycin composition
10/20/2011	WO2011128810A1 Statins for the prevention or treatment of drug addictions
10/20/2011	WO2011128782A2 Compositions and methods for treating type ii diabetes and related disorders
10/20/2011	WO2011128780A1 Crystalline ingenol mebutate
10/20/2011	WO2011128714A1 Stabilised polyphenol derivatives, process for their manufacture, and uses thereof
10/20/2011	WO2011128633A2 Oral pharmaceutical dispersion compositions
10/20/2011	WO2011128629A2 Lipid-vectored drug compositions
10/20/2011	WO2011128628A2 Gelled oral pharmaceutical compositions
10/20/2011	WO2011128627A2 Oral veterinary pharmaceutical and nutraceutical compositions
10/20/2011	WO2011128626A1 Essential fatty acid gelled composition
10/20/2011	WO2011128625A2 Divisible oral pharmaceutical compositions
10/20/2011	WO2011128458A1 Compounds for prevention of cell injury
10/20/2011	WO2011128455A1 Novel compounds for the treatment of diseases associated with amyloid or amyloid-like proteins
10/20/2011	WO2011128445A1 Inhibitors of the accumulation of sprd transcripts in s. aureus
10/20/2011	WO2011128436A1 Combination of hypoxia-inducible factor-1 inhibitors and toll-like receptor-3 agonists for treating solid tumors
10/20/2011	WO2011128434A2 Treatment of endocrine resistant breast cancer
10/20/2011	WO2011128424A1 Methods and compositions for improving implant osseointegration
10/20/2011	WO2011128421A1 Tricyclic pyridyl-vinyl pyrroles as par1 inhibitors
10/20/2011	WO2011128420A1 Pyridyl-vinyl pyrazoloquinolines as par1 inhibitors
10/20/2011	WO2011128413A1 Process for the production of polymorph form i of agomelatine
10/20/2011	WO2011128405A1 Combination of organic compounds
10/20/2011	WO2011128403A1 Organic compound for use in the treatment of liver cancer
10/20/2011	WO2011128395A1 N- substituted 3-amino 4 - ( pyrrolidine - 1 - carbonyl) pyrrolidine and its derivatives for use in the treatment of metabolic disorders

1 ... 1512 1513 1514 1515 1516 1517 1518 1519 1520 1521 1522 1523 1524 1525 1526 1527 1528 1529 1530 1531 1532 ... 7860